Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Single chain antibody-lidamycin fusion protein ER (Fv-LDP) targeting EGFR

A fusion protein and single-chain antibody technology, applied in the field of fusion protein ER, to promote tumor cell apoptosis, good clinical application prospects, and inhibit tumor growth

Inactive Publication Date: 2009-09-23
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the fusion protein ER (Fv-LDP) and its enhanced fusion protein ER (Fv-LDP-AE) that link the anti-EGFR single-chain antibody with lidamycin to become an anti-tumor drug have not been seen so far. related reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Single chain antibody-lidamycin fusion protein ER (Fv-LDP) targeting EGFR
  • Single chain antibody-lidamycin fusion protein ER (Fv-LDP) targeting EGFR
  • Single chain antibody-lidamycin fusion protein ER (Fv-LDP) targeting EGFR

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] . Construction, screening and identification of EGFR phage antibody library

[0130] 1.1 Immunization of mice

[0131] The cultured A431 cells were collected, and each mouse was intraperitoneally injected with 1×10 cells 7 indivual. Booster immunization 2 weeks later. On the 7th day after the last immunization, the mouse eye vein blood was taken to measure the titer by ELISA, and the titer reached 10 5 The spleens of the above mice were used for later use.

[0132]1.2 Phage antibody library construction, screening and identification

[0133] According to the instructions of the Expression Module / Recombinant Phage Antibody system kit from Pharmacia, the construction of the phage library and the screening of anti-EGFR antibodies were carried out. The brief steps are as follows:

[0134] Spleen RNA extraction from the above immunized mice→mRNA purification+OligdT→cDNA synthesis+library construction primer mixture→VH, VL→scFv→scFv+pCANTAB 5E (phagemid Pharmacia produc...

Embodiment 2

[0137] . Construction of fusion protein ER (Fv-LDP) recombinant expression plasmid

[0138] The recombinant plasmid pET-30a(+)-LDP contains the LDP gene and is preserved by our laboratory. The recombinant phagemid pCANTAB 5E contains the scFv gene, and two restriction sites, NdeI and EcoRI, were introduced by PCR (primers were synthesized by Invitrogen).

[0139] scFv 5' end primer (PH1): 5'GGAATTC CATATG GCCCAGGTCCAGCTGCAG 3′

[0140] Nde I

[0141] scFv 3' end primer (PL2): 5'CG GAATTC GGATCCGCCACCGCC CCGTTTTATTTTCCAAC

[0142] TTTGT 3′ EcoR I spacer

[0143] The recombinant phagemid pCANTAB 5E-scFv was used as a template, PH1 was used as the 5' end primer, and PL2 was used as the 3' end primer for PCR amplification to obtain a single-chain antibody gene fragment with a small peptide spacer at the C-terminus. The PCR reaction system was pre-denaturation at 94°C for 2 minutes, followed by 30 cycles of PCR: denaturation at 94°C for 1 minut...

Embodiment 3

[0144] . Fusion protein ER (Fv-LDP) in Escherichia coli BL21 (DE3) star TM inducible expression

[0145] The identified recombinant plasmid was transformed into Escherichia coli BL21(DE3)star TM (Invitrogen company product), randomly pick recombinant transformants and inoculate into 3 ml of LB medium containing 50 μg / ml kanamycin, and culture overnight at 37° C. with shaking. The next day they were inoculated at a ratio of 1:50, cultured with shaking at 37°C until the OD600 was 0.8, added IPTG to a final concentration of 0.8mM, and induced for 4-6 hours. Take an appropriate amount of bacterial liquid, and perform localization analysis of expression products on whole bacteria, medium supernatant, periplasmic cavity components, soluble cytoplasmic components and inclusion bodies. 10% SDS-PAGE electrophoresis analysis of exogenous protein expression The fusion protein was expressed in the inclusion body in an insoluble form ( Figure 4 ). Quantitative analysis of the gel imag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to fusion protein ER (Fv-LDP) and reinforced fusion protein ER (Fv-LDP-AE) thereof. The fusion protein consists of anti-EGFR single chain antibody scFv, lidamycin apoprotein LDP and carboxyl terminal hexahistine; the overall length of gene is 1089 bp, and 363 amino acids are coded; the reinforced fusion protein comprises fusion protein ER (scFv-LDP) (molecular weight about 38 kDa) and activated enediyne chromophore AE (molecular weight 843 Da); in vivo test and in vitro test demonstrate that the fusion protein and the reinforced fusion protein thereof have strong killing effects on EGFR over-expression tumor cell, have significant efficacies on animal in vivo test, and can be developed into targeting drug of miniaturized antibody with high clinical efficiency.

Description

Technical field: [0001] The present invention relates to a fusion protein ER (Fv-LDP), specifically, said fusion protein contains an anti-EGFR single-chain antibody and the amino acid sequence of lidamycin prosthetic protein; [0002] The present invention also relates to a strengthened fusion protein ER (Fv-LDP-AE) that can be prepared through molecular strengthening containing enediyne chromophore (AE); [0003] The invention also relates to the application of said fusion protein and its strengthened fusion protein in tumor targeting therapy. Background technique: [0004] Epidermal growth factor receptor (EGFR) is a multifunctional glycoprotein present on the cell membrane, also known as HER1 or ErbB-1. EGFR and its ligands are part of the cell signal transduction system, and its signal transduction network plays an important role in the formation and development of tumors. EGFR is overexpressed in many types of human tumors including head and neck squamous cell carcino...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/70C12P21/02C07K1/13A61K38/16A61K47/48A61P35/00C12R1/19A61K47/42
Inventor 盛唯瑾甄永苏苗庆芳商悦赵春燕李毅
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com